Ranked by reported Q4 2025 13F market value
Share of total reported institutional value in XTLB held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | CITADEL ADVISORS LLC | 76K | $44K | β | 68.953% | 0.00% |
| 2 | RHUMBLINE ADVISERS | 30K | $17K | +74.4% | 27.365% | 0.00% |
| 3 | GAMMA Investing LLC | 13K | $7K | β | 11.713% | 0.00% |
| 4 | XTX Topco Ltd | 10K | $6K | β | 9.305% | 0.00% |
| 5 | MORGAN STANLEY | 2K | $1K | -82.6% | 1.581% | 0.00% |
| 6 | Noked Israel Ltd | 199K | $115 | 0.0% | 180.766% | 0.02% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). β% of Fundβ shows how much of that investorβs total 13F portfolio is invested in XTLB β a direct measure of their conviction.
Filings activity in XTLB during Q4 2025, grouped by how each filer changed its position.
8 quarters of 13F filings Β· Ξ columns show change vs prior quarter
| Quarter | Inst. Holders | Ξ Holders | Ownership % | Ξ Ownership | Total 13F Value | Ξ Value |
|---|---|---|---|---|---|---|
| Q4 2025 | 6 | +50% | 32.43% | +18.33 pp | $0M | +130% |
| Q3 2025 | 4 | 20% | 14.10% | 0.55 pp | $0M | 3.8% |
| Q2 2025 | 5 | +0.0% | 14.65% | 11.34 pp | $0M | 44% |
| Q1 2025 | 5 | +25% | 25.99% | +0.33 pp | $0M | +1.3% |
| Q4 2024 | 4 | +0.0% | 25.66% | 8.42 pp | $0M | 25% |
| Q3 2024 | 4 | 20% | 34.08% | 21.76 pp | $0M | 39% |
| Q2 2024 | 5 | 17% | 55.84% | 16.41 pp | $0M | 23% |
| Q1 2024 | 6 | β | 72.25% | β | $0M | β |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Ξ columns compare to the immediately prior filed quarter.
Quick answers to the most common questions about buying XTLB stock.
Based on Q4 2025 13F filings, institutional ownership of XTL Biopharmaceuticals Ltd. stands at 32.4%, held across 6 reporting institutions.
CITADEL ADVISORS LLC is the largest reported institutional holder of XTLB, with approximately 75,866 shares worth $0.00B as of Q4 2025.
Yes β 1 widely-followed marquee investor appear among the top 25 institutional holders of XTLB, including CITADEL ADVISORS LLC.
Our composite Smart Money Score for XTLB is 67 out of 100 (Bullish). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
3 institutions opened new positions in XTLB during Q4 2025, while 1 fully exited. 0 added to existing positions and 3 trimmed.
XTLB institutional ownership rose by 18.33 percentage points quarter-over-quarter, with a net change of +2 holders.
The top 10 institutions account for 100.0% of all reported 13F value in XTLB, and the top 25 account for 100.0%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.
XTL Biopharmaceuticals Ltd. (XTLB) Institutional Ownership